Genetic polymorphisms in mediators of inflammation and gastric precancerous lesions

European Journal of Cancer Prevention

Volumn 17, Issue 2, 2008, Pages 178-183

  Canzian, Federico ^a   Franceschi, Silvia ^b   Plummer, Martyn ^b   Van Doorn, Leen Jan ^c   Lu, Yanhui ^b   Gioia Patricola, Lydie ^b   Vivas, Jorge ^d   Lopez, Gladys ^d   Severson, Richard K ^e   Schwartz, Ann G ^e,f   Muñoz, Nubia ^b   Kato, Ikuko ^e,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c DDL DIAGNOSTIC LABORATORY   (Netherlands)

^d Cancer Control Center of the Tachira State   (Venezuela)

^e WAYNE STATE UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase; Gastric premalignant lesions; Genetic polymorphisms; Helicobacter pylori; Interferon ; Nitric oxide synthase

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BACTERIAL INFECTION; CANCER RISK; CANCER STAGING; CHRONIC INFLAMMATION; CONFIDENCE INTERVAL; DYSPLASIA; GASTRITIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOGENESIS;

ADULT; AGED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; INTERFERON TYPE II; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; RECEPTORS, INTERFERON; RISK FACTORS; STOMACH NEOPLASMS; VENEZUELA;

EID: 39749164065     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3282b6fd88     Document Type: Article

References (31)

1. Akhtar M, Newton JC, McGee DJ, Mobley HLT, Gobert AP, Cheng Y, et al. (2001). vacA and urease released by H. pylori stimulate COX-2 expression in macrophages. Gastroenterology 120:A99.
2. Arora S, Czinn SJ (2005). Vaccination as a method of preventing Helicobacter pylori-associated gastric cancer. Cancer Epidemiol Biomarkers Prev 14:1890-1891.
3. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. (1990). Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50:4737-4740.
4. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420:860-867.
5. Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, Canzian F (2005). Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol 11:6003-6008.
6. De Sanjose S, Munoz N, Sobala G, Vivas J, Peraza S, Cano E, et al. (1996). Antioxidants, Helicobacter pylori and stomach cancer in Venezuela. Eur J Cancer Prev 5:57-62.
7. Esumi H, Tannenbaum SR (1994). U.S.-Japan Cooperative Cancer Research Program: seminar on nitric oxide synthase and carcinogenesis. Cancer Res 54:297-301.
8. Franco L, Talamini G, Carra G, Doria D (1999). Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection. Prostaglandins Other Lipid Mediat 58:9-17.
9. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ (2000). Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47:762-770.
10. Jüliger S, Bongartz M, Luty AJ, Kremsner PG, Kun JF (2003). Functional analysis of a promoter variant of the gene encoding the interferon-gamma receptor chain I. Immunogenetics 54:675-680.
11. Karttunen R, Karttunen T, Ekre HP, MacDonald TT (1995). Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36:341-345.
12. Kato I, van Doorn LJ, Canzian F, Plummer M, Franceschi S, Vivas J, et al. (2006). Host-bacterial interaction in the development of gastric precancerous lesions in a high risk population for gastric cancer in Venezuela. Int J Cancer 119:1666-1671.
13. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. (2007). A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
14. Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, et al. (2006). The cyclooxygenase-2 (PTGS2) 8473T >C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392-1394.
15. Lu Y, Gioia-Patricola L, Gomez JV, Plummer M, Franceschi S, Kato I, et al. (2005). Use of whole genome amplification to rescue DNA from plasma samples. Biotechniques 39:511-515.
16. Muñoz N, Vivas J, Buiatti E, Kato I, Oliver W (1996). Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. In: Stewart BW, McGregor D, Kleihues P, editors. Principles of chemoprevention. Lyon: IARC Press; pp. 125-133. IARC Sci Publ No. 139.
17. Obonyo M, Guiney DG, Harwood J, Fierer J, Cole SP (2002). Role of gamma interferon in Helicobacter pylori induction of inflammatory mediators during murine infection. Infect Immun 70:3295-3299.
18. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631-1636.
19. Parkin DM, Bray F, Ferlay J, Pisani P (2000). Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153-156.
20. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, et al. (2004). Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 53:1082-1089.
21. Rosenzweig SD, Schaffer AA, Ding L, Sullivan R, Enyedi B, Yim JJ, et al. (2004). Interferon-gamma receptor 1 promoter polymorphisms: population distribution and functional implications. Clin Immunol 112:113-119.
22. Sawai N, Kita M, Kodama T, Tanahashi T, Yamaoka Y, Tagawa Y, et al. (1999). Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 67:279-285.
23. Shen J, Wang RT, Wang LW, Xu YC, Wang XR (2004). A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. World J Gastroenterol 10:3278-3283.
24. Shtrichman R, Samuel CE (2001). The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol 4:251-259.
25. Thye T, Burchard GD, Nilius M, Muller-Myhsok B, Horstmann RD (2003). Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. Am J Hum Genet 72:448-453.
26. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. (2002). Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 20:409-410.
27. Van Doorn LJ, Figueiredo C, Rossau R, Jannes G, van Asbroek M, Sousa JC, et al. (1998). Typing of Helicobacter pylori vacA gene and detection of cagA gene by PCR and reverse hybridization. J Clin Microbiol 36:1271-1276.
28. Van Doorn LJ, Figueiredo C, Sanna R, Blaser MJ, Quint WG (1999). Distinct variants of Helicobacter pylori cagA are associated with vacA subtypes. J Clin Microbiol 37:2306-2311.
29. Wallace JL, Bell CJ (1996). Gastroduodenal mucosal defence. Curr Opin Gastroenterol 12:503-511.
30. Wigginton JE, Cutler DJ, Abecasis GR (2005). A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76:887-893.
31. Williams CS, DuBois RN (1996). Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270:G393-G400.